Should be good. Company is now on solid financial footing. There should be an upward trend over the next few months, as AEMD becomes more and more attractive to early investors who have been watching DARPA program and clinical trials progress. Then there should be a nice bump up when uplisted to NASDAQ and major news on safety trials, procurements, etc. is released. There is also potential for significant news out of India.
News 
Market Data 
Discover 
AI
